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Abstract. Extracellular vesicles (EVs) are now recognized 
as a fundamental way for cell-to-cell horizontal transfer of 
properties, in both physiological and pathological condi-
tions. Most of EV-mediated cross-talk among cells depend 
on the exchange of proteins, and nucleic acids, among which 
mRNAs, and non-coding RNAs such as different species 
of miRNAs. Cancer cells, in particular, use EVs to discard 
molecules which could be dangerous to them (for example 
differentiation-inducing proteins such as histone H1.0, or 
antitumor drugs), to transfer molecules which, after entering 
the surrounding cells, are able to transform their phenotype, 
and even to secrete factors, which allow escaping from 
immune surveillance. Herein we report that melanoma cells 
not only secrete EVs which contain a modified form of H1.0 
histone, but also transport the corresponding mRNA. Given 
the already known role in tumorigenesis of some RNA 
binding proteins (RBPs), we also searched for proteins of 
this class in EVs. This study revealed the presence in A375 
melanoma cells of at least three RBPs, with apparent MW 
of about 65, 45 and 38 kDa, which are able to bind H1.0 
mRNA. Moreover, we purified one of these proteins, which 
by MALDI-TOF mass spectrometry was identified as the 
already known transcription factor MYEF2.
Introduction
Most eukaryotic cells are now recognized to shed extracel-
lular vesicles (EVs) into their environment (1,2). Among these 
vesicles, some are known as membrane vesicles (MVs) or 
ectosomes and originate from the plasma membrane, through 
a process resembling viral budding, whereas a second class 
consists of smaller vesicles (exosomes), which are released 
after plasma membrane fusion of the so-called multivesicular 
bodies (MVBs), which originate in the endosomal compart-
ment (3).
Production of EVs, initially discovered in transformed 
cells, has been demonstrated as a physiological mechanism 
involved in the horizontal transfer of several kinds of molecules 
in normal cells, among which different classes of cells in the 
nervous system (4-7). Cancer cells, however, produce and 
release much higher amounts of EVs (8), which can reach most 
biological fluids, such as blood plasma (9), breast milk (10), and 
saliva (11,12), where they could be used as biological markers 
of disease and even of the disease grade (13-15).
Concerning protein content, EVs released from cancer 
cells transport different classes of chaperones, tumor-
specific antigens, apoptosis-inducing proteins, such as FasL 
and TRAIL (16,17), immune modulatory factors (18), and 
many other oncogenic molecules, which, once transferred 
into surrounding cells, can facilitate cancer development by 
suppressing immune responses, and stimulating tumor growth, 
invasion and metastasis.
Recently, we reported that oligodendroglioma cells release 
into EVs also the H1.0 linker histone variant (19). H1 linker 
histones constitute in mammals the most heterogeneous family 
of histones. In humans, the H1 family includes 11 members, 
among which 7 are expressed in somatic cells (H1.1-H1.5; H1.0 
and H1X), 3 are specifically expressed in testis, and one is 
specifically expressed in the oocyte (H1.oo) (20-22). Moreover, 
among the somatic subtypes, H1.1-H1.5 are encoded by 
repeated genes which are transcribed during the S phase of the 
cell cycle, in a replication-dependent manner, to give mRNAs 
which are not polyadenylated. On the other hand, H1.0 is tran-
scribed in a replication-independent way, into a polyadenylated 
mRNA (23), and is prevalent in differentiated cells.
The presence of H1.0 in the EVs produced by oligoden-
droglioma cells suggested, on one hand, that deregulation of 
H1.0 histone expression can be linked to tumorigenesis, and, 
on the other, that cancer cells can escape differentiation by 
discarding this protein into EVs (19). To shed more light on this 
hypothesis, in this study we analyzed a different kind of cancer 
cells: A375 melanoma cells. Here we report that these cells 
synthesize H1.0 histone and secrete a modified form of it into 
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MVs. In addition, we found that EVs released from melanoma 
cells also contain H1.0 mRNA. Since post-transcriptional 
regulation of mRNA trafficking, stability and translation 
depends on a number of RNA-binding proteins (RBPs) (24), 
and since a group of H1.0 mRNA-binding proteins have been 
already found in the rat brain (25-28), we also looked for RBPs 
with this ability in melanoma cells and EVs. Here we show 
that H1.0-binding RBPs are indeed present in the EVs released 
from A375 melanoma cells, and that one of these proteins is 
MYEF2.
Materials and methods
Cell cultures. A375 melanoma cells (A375CL1006) were 
cultured in Dulbecco's modified Eagle's medium - low 
glucose (DMEM 5546, Sigma-Aldrich, MO, USA) supple-
mented with 10% heat-inactivated fetal bovine serum (F7524 
Sigma-Aldrich), 2 mM glutamine (Euroclone, Milan, Italy), 
0.1% MEM non essential amino acids (Sigma-Aldrich), 1 mM 
sodium pyruvate (Euroclone), 100,000 U penicillin, 100 mg 
streptomycin and 250 µg amphotericin B (Sigma-Aldrich) 
per liter. Cells were maintained in humidified 5% CO2/95% air, 
at 37˚C. Some A375 melanoma cells were cultured in the same 
medium without serum.
Immunofluorescence analyses. Cells were fixed in 96% 
ethanol and immune-stained with rat anti-integrin β1 (1:100; 
in-house produced), and rabbit anti-H1˚ (1:100; sc-67324 Santa 
Cruz, CA, USA).
The secondary antibodies used were f luorescein 
isothiocyanate-conjugated anti-rat-(1:100; F1763), or rhoda-
mine-conjugated anti-rabbit-(1:200; T6778) immunoglobulins 
(both from Sigma, MO, USA).
Nuclei were stained with 4',6-diamidino-2-phenylindole 
dihydrochloride (DAPI) (H1200, Vector Laboratories, 
Youngstown, OH, USA). Cells were observed in an Olympus 
BX-50 microscope (Olympus Italia S.r.l., Segrate, Italy) 
equipped with Vario Cam B/W camera (Nikon Instruments 
S.p.A., Calenzano, Italy).
Preparation of microvesicles from the A375 medium. Vesicles 
were prepared from A375 FBS-free conditioned medium, 
as follows: 24 h before collecting media, cells were washed 
twice in phosphate-buffered saline (PBS), pH 7.5, and then 
incubated with FCS-free DMEM. Conditioned media were 
centrifuged at 2,000 x g for 10 min and then at 4,000 x g for 
15 min. The supernatant was centrifuged at 105,000 x g (Ti70 
Rotor, Beckman) for 90 min at 4˚C.
To separate exosomes from MVs, before ultracentrifuga-
tion, medium was filtered with a 0.2-µm filter and centrifuged 
at 10,000 x g for 30 min. The pellet containing MVs was saved 
while the supernatant was finally centrifuged at 105,000 x g 
for 90 min to obtain exosomes.
Pelleted vesicles were suspended in PBS and protein 
concentration was determined using Qubit® Protein assay kit 
(Q33211, Invitrogen, OR, USA).
Vesicles analyses. The NS300 (NanoSight, London, UK) 
instrument is based on a conventional optical microscope and 
uses a laser light source to illuminate nano-scale particles. This 
analysis allowed measuring size and concentration of vesicles 
in a liquid medium based on tracking of Brownian motion.
Purification of total cell extracts. Cells were collected and 
homogenized in nuclei buffer (0.32 M sucrose; 50 mM sodium 
phosphate buffer, pH 6.5; 50 mM KCl; 0.5 mM spermine; 
0.15 mM spermidine; 2 mM EDTA; 0.15 mM EGTA), 
containing the protease inhibitors aprotinin (2 µg/ml), antipain 
(2 µg/ml), leupeptin (2 µg/ml), pepstatin A (2 µg/ml), benzami-
dine (1.0 mM), and phenylmethylsulfonyl fluoride (1.0 mM), 
all purchased from (Sigma-Aldrich). Protein concentration 
was determined according to Bradford (29).
Western blot analysis. Proteins (15 µg) were separated by 
electrophoresis on denaturing 12.5% polyacrylamide slab gels 
(SDS-PAGE) and transferred to PVDF membrane (IPVH00010, 
Immobilon P, Millipore, MA, USA), as previously described 
(19). Samples on the membrane were visualized by staining 
with Ponceau Red (Sigma-Aldrich) for 5 min. Membranes were 
immune-stained with rabbit polyclonal anti-H1˚ antibodies 
(1:500, sc-67324 Santa Cruz), mouse monoclonal anti-Hsc70 
antibodies (1:1,000, sc-7298, Santa Cruz), rabbit polyclonal 
anti-SUMO1 (1:500, S373B, Santa Cruz). The secondary anti-
bodies were AP-conjugated anti-mouse (1:7,500, S372B) and 
anti-rabbit (1:7,500, S373B) IgGs (Promega Corp., Madison, 
WI, USA).
Reverse transcription (RT)-PCR. Total RNA was purified 
from cells according to Chomczynski and Sacchi (30). RNA 
from vesicles was prepared using either the Pure-Link RNA 
microKit (12183016, Invitrogen) or the TRIzol® reagent 
(15596-018, Invitrogen), according to the manufacturer's 
instructions.
Synthesis of cDNA was performed using the Superscript II 
Reverse Transcriptase kit (18064-022 Invitrogen), following 
the manufacturer's protocol. The primer used for the reverse 
transcription had the following sequence: (5'→3') GGC TTT 
CTT GGG CGT GGC AGC C.
PCR was performed using Taq DNA polymerase 
(10342-020, Invitrogen), according to the manufacturer's 
instructions, and using the following primers: forward, (5'→3'), 
ATG ATC GTG GCT GCC ATC CAG GC; reverse, (5'→3'), 
GGC TTT CTT GGG CGT GGC AGC C.
Amplification was performed by Mastercycler Thermal 
Cycler 5345 (Eppendorf AG, Hamburg, Germany) using the 
following program: 94˚C for 30 sec, 35 cycles at 95˚C for 
30 sec, 52˚C for 30 sec, 72˚C for 30 sec, and 72˚C for 5 min.
Preparation of in vitro transcripts and T1 RNase protection 
assay. 33P-radiolabeled H1.0 RNA was prepared as previ-
ously described (25), using as a template the plasmid pMH1.0 
(31), which contains the H1.0 insert (EMBL ID: X70685). In 
order to prepare H1.0 mRNA to be used for chromatographic 
experiments, in some reactions transcription was performed 
in the presence of biotin-21-UTP (AM8450, Ambion-Life 
Technologies, Paisley, UK), a UTP analog which has biotin 
attached to the pyrimidine ring by a 21-atom spacer arm (27).
For T1 RNase (EC 3.1.27.3; Roche, Switzerland) protec-
tion assay, radiolabeled H1.0 RNA was mixed with either 
total cell extracts or vesicles (15 µg), prepared as described 
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above, following the procedure previously described (32). 
RNA-protein complexes were analyzed by denaturing electro-
phoresis on sodium dodecyl sulfate (SDS)-polyacrylamide slab 
gel (PAGE). At the end of the run, the gel was directly exposed 
to X-ray film for autoradiography (Amersham Hyperfilm™, 
GE Healthcare, USA). The gels were stained with Coomassie 
Brilliant Blue R-250 (Sigma-Aldrich), to confirm loading of 
equal amounts of proteins per lane.
Chromatographic purification from A375 cell-released EVs 
of H1.0 RNA-binding factors. Streptavidin-conjugated para-
magnetic beads (z5481, Magnesphere, Promega) were washed 
three times in PBS according to the manufacturer's instruc-
tions, and then mixed with 450 µg of A375 EV proteins, in 
500 µl (final volume) of binding buffer (BB: 75 mM Tris-HCl, 
pH 7.5; 50 mM KCl; 5 mM dithiothreitol) (27), containing 
proteases and phosphatases inhibitors (Sigma-Aldrich). 
Samples were incubated for 1 h, at 4˚C, under shaking, to allow 
unspecific protein binding to the particles (pre-clearing step). 
After centrifuging at 10,000 x g for 5 min, the pre-cleared 
supernatants were used for the specific binding reaction. The 
pre-cleared sample was divided into two aliquots, one of which 
was mixed with H1.0 RNA (1.2 µg) in BB, while the other one 
was used as an RNA-free control. Both samples were incu-
bated for 1 h at 4˚C, after which fresh aliquots of pre-washed 
beads were added, and incubation was continued for 1 h, at 4˚C, 
under shaking. Finally, the supernatants containing unbound 
proteins were collected by a magnetic device (Magnesphere, 
Promega) and frozen. Paramagnetic beads were washed four 
times in BB and then resuspended in electrophoresis sample 
buffer, boiled and centrifuged at 10,000 x g. The supernatants, 
which contain bound proteins, were frozen and saved for 
analyses.
Silver staining. After SDS-PAGE, the gel was silver stained 
according to Yan et al (33). The region of interest was cut from 
the gel and analyzed by MALDI-TOF mass spectrometry.
MALDI-TOF mass spectrometry. MALDI-TOF mass spec-
trometry analysis was performed using the Voyager DE-PRO 
(Applied Biosystems, Foster City, CA, USA) mass spec-
trometer as previously described (34). Briefly, silver stained 
band was in gel-destained with K3[Fe(CN)6] and Na2S2O3, 
reduced with dithiothreitol, S-alkylated with iodoacetamide, 
and subsequently digested with trypsin. The tryptic peptide 
extracts were desalted by µzip-TipC18 (Millipore) and loaded 
on the MALDI target, using the dried droplet technique and 
α-cyano-4-hydroxycinnamic acid as matrix. The resulting 
mass spectrum, was elaborated using the DataExplorer 
software (Applied Biosystems) and manually inspected to 
obtain the corresponding peak lists. Internal mass calibration 
was done using trypsin autolysis fragments at m/z 842.5100, 
1045.5642, and 2211.1046 Da. Peptide mass fingerprinting was 
compared to the theoretical masses from the Swiss-Prot.
Results
A375 melanoma cells release both membrane vesicles (MVs) 
and exosomes. As shown in Fig. 1, A375 melanoma cells 
produce and release into the culture medium extracellular 
vesicles, at least in part from plasma membrane regions 
enriched in integrin β1 (Fig. 1A-C). The vesicular popula-
tion is actually a mixed one, as demonstrated by NanoSight 
(Fig. 1D), which allowed measuring size and concentration of 
vesicles in the culture medium, based on tracking of Brownian 
motion. In addition, according to the NanoSight data (which 
are quantitative), the EV population is composed mainly of 
exosomes (compare the height of the peak at 103-131 nm, 
which corresponds to exosomes, with the shoulder at 270 nm, 
which probably corresponds to MVs). In some experiments, 
the medium in which melanoma cells had been cultured 
was filtered and centrifuged at 10,000 x g for 30 min, before 
ultracentrifugation, in order to pellet first only MVs. The 
supernatant was then centrifuged at 105,000 x g for 90 min to 
obtain a final pellet of exosomes. The NanoSight analysis of 
the separated fractions gave only single peaks (Fig. 1D, right 
panel, where only the analysis concerning purified exosomes 
is shown). The relative concentrations (expressed as µg/µl 
of proteins) of the two populations of vesicles obtained are 
reported in Fig. 1E.
EVs released from A375 melanoma cells contain both H1.0 
linker histone and the corresponding mRNA. H1.0 linker 
histone was first discovered in non-dividing tissues (35,36), 
and, in general, accumulates in differentiating cells at the 
end of the proliferative phase. Recently, it was however 
found in total cell extracts and extracellular vesicles from 
G26/24 dividing oligodendroglioma cells (19). In this study 
we therefore looked for the possibility that also melanoma 
cells synthesize and secrete this histone via EVs. As shown 
in Fig. 2, A375 cells indeed produce a protein which is 
immune-stained by anti-H1.0 antibodies both in immuno-
fluorescence (Fig. 2A-C) and western blot analyses (Fig. 2D). 
As already reported for other tumor cells, melanoma cells 
release EVs (both MVs and exosomes) which contain the 
Hsc70 chaperone (19). Interestingly, they also secrete an 
anti-H1.0 antibody-positive protein which, however, is larger 
than expected, and is specifically sorted to MVs. Since other 
proteins sorted to vesicles bear specific post-translational 
modifications, such as sumoylation (37), we looked for the 
presence of a SUMO moiety on this larger H1.0. As shown 
in Fig. 2E, anti-SUMO1 antibodies not only recognized a 
protein of about 38 kDa, but this band exactly co-migrates 
with the slow migrating protein recognized by the anti-H1.0 
antibodies (Fig. 2E, asterisk).
We then analyzed both total cell lysates and the vesicular 
fraction for the presence of H1.0 mRNA. We used as a template 
for reverse transcription (RT)-PCR total RNA prepared from 
either whole melanoma cells or EVs (MVs plus exosomes). As 
shown in Fig. 3, a band of the expected size [380 base pairs 
(bp)] was found both in cells (Fig. 3A, A375L) and vesicles 
(Fig. 3B, A375v), thus indicating that, indeed, not only H1.0 
protein but also the corresponding mRNA was sorted to EVs. 
As internal references for these RT-PCR experiments we used 
two positive controls: total RNA from adult rat brain (Fig. 3A, 
lane B), and the cDNA insert encoding H1.0 (Fig. 3C, lane 
cDNA); one sample which did not contain RNA was included 
in all the experiments as a negative control (Fig. 3B and C, 
lane N). Furthermore, to be sure that we were amplifying 
RNA and not contaminating DNA, we also performed a PCR 
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Figure 2. Expression of H1.0 histone in A375 melanoma cells. (A) A375 melanoma cells were immune-stained with anti-H1.0 antibodies (red fluorescence). 
(B) Cells were also stained with DAPI (blue fluorescence). (C) Overlay of (A) and (B). Bar, 10 µm. (D) Western blot analysis of total cell lysates from A375 
melanoma cells (lane 1), total extracellular vesicles (lane 2), microvesicles (lane 3) and exosomes (lane 4). Proteins were immune-stained with anti-H1.0 
antibodies (H1.0). The upper part of the membrane was cut out and immune-stained with anti-Hsc70 antibodies for internal reference (Hsc70). (E) Western blot 
analysis of total cell lysates from A375 melanoma cells and microvesicles. Twin samples of melanoma cells (lane 1) and microvesicles (lane 3) were separated 
by electrophoresis and blotted onto PVDF membrane. The membrane was then cut into two halves, each of which was incubated with either anti-SUMO1- or 
anti-H1.0-antibodies. Samples 1 and 3 are the same as those of (D). The asterisk indicates putative sumoylated H1.0.
Figure 1. Analysis of extracellular vesicles produced by A375 melanoma cells. (A) A375 melanoma cells were immune-stained with anti-β1 integrin antibodies 
(green fluorescence). (B) Cells were also stained with DAPI (blue fluorescence). (C) Overlay of (A) and (B). Bar, 10 µm. (D and E) Nanoparticle tracking 
analysis (NTA) of total vesicles and exosomes from A375 melanoma cells. (D) Plot of particles showing size distribution profiles with distinct peaks at 
103, 131 and 270 nm (total vesicles) and 104 nm (exosomes). (E) Grey boxes indicate average concentrations (expressed as µg/µl of proteins) of membrane 
vesicles (MVs) and exosomes (Exo) from at least 3 experiments; standard deviation is also indicated (black boxes).
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reaction not preceded by the RT step; in these PCR control 
experiments no band was seen (Fig. 3C, A375v).
EVs released from A375 melanoma cells also contain H1.0 
mRNA-binding proteins. The presence of H1.0 RNA in EVs 
prompted us to also look for RNA-binding proteins (RBPs) 
in the vesicles. We applied a T1 RNase protection assay 
used by us for many years to study protein-RNA interac-
tions (25,32). Briefly, proteins from freeze fractured vesicles 
were incubated with ~5.0x106 cpm of 33P-labeled, in vitro 
transcribed H1.0 RNA, in order to allow formation of non-
covalent protein-RNA complexes. The putative complexes 
were then treated with T1 RNase to digest all the RNA but the 
sequences protected by proteins. Finally, the complexes were 
cross-linked by UV treatment and analyzed by denaturing 
PAGE. As shown in Fig. 4, many H1.0 RNA-binding proteins 
are present in melanoma cells (Fig. 4B, lane L); in the vesicles, 
however, only three main bands are clearly visible, at ~65, 
45 and 38 kDa, respectively (Fig. 4B, lane V). In Fig. 4A we 
show the stained proteins present in the same gel that was then 
dried and used for fluorography (Fig. 4B). In this gel a nega-
tive control was also included, which was obtained by treating 
H1.0 RNA with T1 nuclease and UV, but in the absence of 
proteins (Fig. 4B, lane N). Finally, we also probed specificity of 
these bands by repeating the analysis with H1.0 RNA (Fig. 4C, 
H1.0) and, in parallel, with a second RNA (Fig. 4C and D), 
encoding CSD-C2/PIPPin protein (26,38). As clearly shown 
in Fig. 4D, although control RNA (lane C) can be bound by 
several proteins in melanoma cells (Fig. 4D, lane L), no band 
is visible in the vesicle fraction (Fig. 4D, lane V). On the other 
hand, H1.0 RNA (Fig. 4C) again formed the complexes seen 
in Fig. 4B.
Enrichment of the H1.0 RNA-binding proteins present in EVs 
by affinity chromatography and analysis by MALDI-TOF mass 
spectrometry. Then we tried to enrich the H1.0 RNA-binding 
proteins evidenced in EVs by using a protocol based on 
affinity chromatography on biotinylated H1.0 RNA, as already 
described (27). The protein fractions obtained from chro-
matography in the presence (Fig. 5, lane 1) or in the absence 
(Fig. 5, lane 2) of H1.0 RNA were analyzed by SDS-PAGE 
and the gel was silver stained. The region indicated by the 
rectangle in Fig. 5 (lane 1), which clearly contains proteins 
not present in the negative control sample (Fig. 5, lane 2), 
was cut from the gel and analyzed by MALDI-TOF mass 
spectrometry. The highest score was found for myelin expres-
sion factor 2 (MYEF2) (Table I), a protein mainly known as a 
Figure 3. RT-PCR analysis of H1.0 mRNA in A375 melanoma cells and 
vesicles. (A) RT-PCR of RNA from total cell lysates from A375 cells 
(lane A375L) and adult rat brain cortices (lane B). (B) RT-PCR of RNA 
from extracellular vesicles released from A375 cells (lane A375v); a negative 
control was also included (lane N). (C) Amplification by PCR only of RNA 
from purified A375 vesicles (lane A375v), and from the cDNA encoding H1.0 
(lane cDNA). A negative control was also included (lane N). The expected 
size (380 bp) of the amplified fragment is shown.
Figure 4. T1 RNase protection assay. 33P-labeled H1.0 RNA was obtained by 
in vitro transcription from the T3 polymerase promoter of pMH1.0 plasmid, 
purified and mixed with total cell extracts (lane L) or vesicles (lane V) from 
A375 melanoma cells. H1.0 RNA was also treated with T1 RNase in the 
absence of protein (lane N), as a control. (A) Coomassie blue staining of 
the gel shown in (B). (B and C) Fluorography of the SDS-PAGE gels on 
which H1.0 RNA-protein complexes formed by proteins present in the total 
cell lysates (lane L) or in the extracellular vesicles (lane V) were analysed. 
(D) In order to ascertain the degree of specificity of RNA-protein binding, 
both total lysates (lane L) and vesicles (lane V) from A375 melanoma cells 
were also probed with another in vitro transcribed RNA, the one encoding 
CSD-C2 protein (C). This RNA was bound by several proteins when 
incubated with total cell lysates (lane L) but no band is visible in the vesicle 
fraction (lane V).
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DNA-binding repressor of the gene encoding the myelin basic 
protein (39,40).
Finally, we analyzed the proteins present in the freeze 
fractured vesicles from melanoma cells by western blot with 
anti-MYEF2 antibodies. As shown in Fig. 6, indeed, we 
observed three bands immune-stained by these antibodies 
(of ~65, 45 and 34 kDa, respectively).
Discussion
Construction of a complete multicellular organism requires 
a precise and complex array of events which involves cell 
proliferation as well as cell death, cell migration and differen-
tiation, formation of a network of cell-to-cell and cell-to-ECM 
contacts, and exchange of chemical signals of many kinds. 
Among the ways used by cells to exchange information, 
production of extracellular vesicles has been recognized as a 
physiological process, which is highly enhanced in transformed 
cells. Cancer cells rely on EVs production for modifying to 
their own advantage activities and properties of surrounding 
cells. In addition, they probably use EVs to discard proteins 
otherwise able to counteract tumorigenesis. In both normal 
and cancer cells, indeed, the transcriptional potential of the 
cell nucleus is controlled by availability of specific transcrip-
tion factors, and by the structural organization of chromatin. 
The structural organization of chromatin is, in turn, regulated 
by a series of dynamic events, involving chromatin remodel-
ling factors (41) as well as the synthesis and incorporation of 
replacement histone variants (42,43), such as the linker H1.0 
histone, which has been reported, long ago, to be specifically 
accumulated during terminal differentiation of several cell 
types (35,36,44).
Surprisingly, we recently found that in glial tumor cells 
concentration of both H1.0 mRNA and protein is high and not 
linked to a decrease of proliferation rate (19). Moreover, these 
cells secrete H1.0 by sorting it to EVs (19). In this study we 
therefore analysed tumor cells of different origin, A375 mela-
noma cells, and found that also these cells produce H1.0. In 
addition, like oligodendroglioma cells, they secrete it into EVs. 
In this case, however, the histone shows an apparent molecular 
mass higher than expected. Since it has been reported that 
some proteins, specifically sorted to EVs, are modified by 
sumoylation (45), the presence of a SUMO moiety in the puta-
tive H1.0 sorted to EVs was investigated. The obtained results 
suggest that this is indeed the case. We conclude that the still 
unknown mechanism responsible for the direct correlation 
between H1.0 expression and differentiation does not work 
in cancer cells. Moreover, we can hypothesize that secretion 
of EVs from these cells could be also involved in eliminating 
proteins (such as the H1.0 histone) that could be able to coun-
teract proliferation.
Interestingly, as demonstrated by RT-PCR, EVs released 
from melanoma cells also contain H1.0 mRNA. This observa-
tion prompted us to look for H1.0 mRNA-binding proteins. 
We used an affinity chromatography approach that allowed to 
search, only in the presence of a biotinylated RNA, a group of 
Table I. Synopsis of information on the protein identified as MYEF 2.a
Protein name Gene name AC Mowse score Sequence  Theoretical 
    coverage (%) MW (Da)-pI
Myelin expression factor 2 MYEF2 Q9P2K5 136 19 64121-8.86
aProtein name, gene name, AC (accession no.), theoretical MW, and pI are from Swiss-Prot database. Mowse score represent -10* Log (P), 
where P is the probability that the observed match is a random event.
Figure 5. Silver staining of a gel (SDS-PAGE) on which RBPs obtained by 
affinity chromatography were separated. Affinity chromatography was per-
formed on streptavidin-conjugated paramagnetic particles, in the presence 
(lane 1) or not (lane 2) of biotinylated H1.0 RNA, as described in the text.
Figure 6. Western blot analysis of total cell lysates from melanoma cells 
(lane 1) and total extracellular vesicles (lane 2). Proteins were immune-
stained with anti-MYEF2 antibodies (B). Ponceau red-staining of the same 
membrane as shown in (A).
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proteins, which were further analysed by MALDI-TOF mass 
spectrometry. Among these proteins, the most prevalent was 
myelin expression factor 2 (MYEF2). This protein has been 
identified in undifferentiated cells, as a repressor able to bind 
directly to and to repress the promoter of the gene encoding 
the mouse myelin basic protein (39); it also contains two RNA 
recognition motifs (RRM) which were shown to bind DNA 
(40); finally, it has also been reported to form a complex with 
Runt-related transcription factor 1 (RUNX1), an essential 
transcription factor involved in generating hematopoietic stem 
cells (46). On the basis of these previous observations, MYEF2 
expression in cancer cells is not surprising. In addition, since 
this protein contains RNA-recognition motifs, its binding 
to an mRNA is not surprising either. However, the fact that 
this repressor protein, mostly expressed in undifferentiated 
cells, binds to the mRNA encoding the differentiation-linked 
H1.0 histone, probably participating in its elimination from 
the cells via EVs, is in our opinion of great importance and 
sheds new light on the biochemical mechanisms involved in 
tumorigenesis. Moreover, H1.0 mRNA could in turn function 
as a MYEF2-carrier: once entered a new cell, MYEF2 could 
indeed also function as a transcriptional repressor, thus condi-
tioning the expression properties of the receiving cell.
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